Literature DB >> 34334369

Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β2-Adrenergic Receptor Agonists.

Christopher T Szlenk1, Jeevan B Gc1, Senthil Natesan2.   

Abstract

The drugs salmeterol, formoterol, and salbutamol constitute the frontline treatment of asthma and other chronic pulmonary diseases. These drugs activate the β2-adrenergic receptors (β2-AR), a class A G protein-coupled receptor (GPCR), and differ significantly in their clinical onset and duration of actions. According to the microkinetic model, the long duration of action of salmeterol and formoterol compared with salbutamol were attributed, at least in part, to their high lipophilicity and increased local concentrations in the membrane near the receptor. However, the structural and molecular bases of how the lipophilic drugs reach the binding site of the receptor from the surrounding membrane remain unknown. Using a variety of classic and enhanced molecular dynamics simulation techniques, we investigated the membrane partitioning characteristics, binding, and unbinding mechanisms of the ligands. The obtained results offer remarkable insight into the functional role of membrane lipids in the ligand association process. Strikingly, salmeterol entered the binding site from the bilayer through transmembrane helices 1 and 7. The entry was preceded by membrane-facilitated rearrangement and presentation of its phenyl-alkoxy-alkyl tail as a passkey to an access route gated by F193, a residue known to be critical for salmeterol's affinity. Formoterol's access is through the aqueous path shared by other β2-AR agents. We observed a novel secondary path for salbutamol that is distinct from its primary route. Our study offers a mechanistic description for the membrane-facilitated access and binding of ligands to a membrane protein and establishes a groundwork for recognizing membrane lipids as an integral component in the molecular recognition process. SIGNIFICANCE STATEMENT: The cell membrane's functional role behind the duration of action of long-acting β2-adrenergic receptor (β2-AR) agonists such as salmeterol has been a subject of debate for a long time. This study investigated the binding and unbinding mechanisms of the three commonly used β2-AR agonists, salmeterol, formoterol, and salbutamol, using advanced simulation techniques. The obtained results offer unprecedented insights into the active role of membrane lipids in facilitating access and binding of the ligands, affecting the molecular recognition process and thus their pharmacology.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34334369      PMCID: PMC8626642          DOI: 10.1124/molpharm.121.000285

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.054


  89 in total

1.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs.

Authors:  Ron O Dror; Hillary F Green; Celine Valant; David W Borhani; James R Valcourt; Albert C Pan; Daniel H Arlow; Meritxell Canals; J Robert Lane; Raphaël Rahmani; Jonathan B Baell; Patrick M Sexton; Arthur Christopoulos; David E Shaw
Journal:  Nature       Date:  2013-10-13       Impact factor: 49.962

Review 2.  On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.

Authors:  Georges Vauquelin
Journal:  Expert Opin Drug Discov       Date:  2015-07-13       Impact factor: 6.098

3.  A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction.

Authors:  J A van Noord; J J Smeets; F P Maesen
Journal:  Respir Med       Date:  1998-12       Impact factor: 3.415

4.  CHARMM-GUI Membrane Builder for Complex Biological Membrane Simulations with Glycolipids and Lipoglycans.

Authors:  Jumin Lee; Dhilon S Patel; Jonas Ståhle; Sang-Jun Park; Nathan R Kern; Seonghoon Kim; Joonseong Lee; Xi Cheng; Miguel A Valvano; Otto Holst; Yuriy A Knirel; Yifei Qi; Sunhwan Jo; Jeffery B Klauda; Göran Widmalm; Wonpil Im
Journal:  J Chem Theory Comput       Date:  2018-12-28       Impact factor: 6.006

5.  Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells.

Authors:  Alison A Carter; Stephen J Hill
Journal:  J Pharmacol Exp Ther       Date:  2005-07-28       Impact factor: 4.030

Review 6.  Pharmacological similarities and differences between beta2-agonists.

Authors:  J Lötvall
Journal:  Respir Med       Date:  2001-08       Impact factor: 3.415

7.  Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children.

Authors:  J M Henriksen; L Agertoft; S Pedersen
Journal:  J Allergy Clin Immunol       Date:  1992-06       Impact factor: 10.793

8.  Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol.

Authors:  M Isogaya; Y Yamagiwa; S Fujita; Y Sugimoto; T Nagao; H Kurose
Journal:  Mol Pharmacol       Date:  1998-10       Impact factor: 4.436

9.  Benchmarking of Force Fields for Molecule-Membrane Interactions.

Authors:  Markéta Paloncýová; Gabin Fabre; Russell H DeVane; Patrick Trouillas; Karel Berka; Michal Otyepka
Journal:  J Chem Theory Comput       Date:  2014-07-08       Impact factor: 6.006

Review 10.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

View more
  1 in total

1.  Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor Bound to a Negative Allosteric Modulator, ORG27569, and Analogs.

Authors:  Peter Obi; Senthil Natesan
Journal:  J Med Chem       Date:  2022-09-06       Impact factor: 8.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.